SpringWorks Therapeutics (SpringWorks Therapeutics) Cash-to-Debt : 66.53 (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is SpringWorks Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. SpringWorks Therapeutics's cash to debt ratio for the quarter that ended in Mar. 2024 was 66.53.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, SpringWorks Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for SpringWorks Therapeutics's Cash-to-Debt or its related term are showing as below:

SWTX' s Cash-to-Debt Range Over the Past 10 Years
Min: 57.62 Med: 209.85 Max: No Debt
Current: 66.53

During the past 7 years, SpringWorks Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 57.62. And the median was 209.85.

SWTX's Cash-to-Debt is ranked better than
75.64% of 1535 companies
in the Biotechnology industry
Industry Median: 6.49 vs SWTX: 66.53

SpringWorks Therapeutics Cash-to-Debt Historical Data

The historical data trend for SpringWorks Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

SpringWorks Therapeutics Cash-to-Debt Chart

SpringWorks Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

185.99

289.31

112.78

67.90

SpringWorks Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															74.91	62.67	57.62	67.90	66.53

Competitive Comparison of SpringWorks Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, SpringWorks Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SpringWorks Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SpringWorks Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where SpringWorks Therapeutics's Cash-to-Debt falls into.

SpringWorks Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

SpringWorks Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	479.202	/	(1.061	+	5.996)
	=	67.90

SpringWorks Therapeutics's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	436.583	/	(0.981	+	5.581)
	=	66.53

SpringWorks Therapeutics (NAS:SWTX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

SpringWorks Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of SpringWorks Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

SpringWorks Therapeutics (SpringWorks Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SpringWorks Therapeutics Inc (NAS:SWTX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Washington Boulevard, Stamford, CT, USA, 06902

Website

https://www.springworkstx.com

SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.

Executives

Tai-an Lin	officer: Chief Scientific Officer	C/O SPRINGWORKS THERAPEUTICS, INC., 100 WASHINGTON BOULEVARD, STAMFORD CT 06902
Julie Hambleton	director	C/O FIVE PRIME THERAPEUTICS, INC., TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Jeffrey Lawrence Schwartz	director, 10 percent owner	C/O BAIN CAPITAL LIFE SCIENCES, LP, 200 CLARENDON STRERET, BOSTON MA 02116
Daniel Pichl	officer: Chief People Officer	C/O SPRINGWORKS THERAPEUTICS, INC., 100 WASHINGTON BLVD., STAMFORD CT 06902
James Cassidy	officer: Chief Medical Officer	368 NOD HILL ROAD, WILTON CT 06897
Orbimed Advisors Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carlos Alban	director	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Saqib Islam	director, officer: Chief Executive Officer	ALEXION PHARMACEUTICALS, 352 KNOTTER DRIVE, CHESHIRE CT 06410
L. Mary Smith	officer: See Remarks	C/O SPRINGWORKS THERAPEUTICS, INC., 100 WASHINGTON BLVD., STAMFORD CT 06902
Bain Capital Life Sciences Investors, Llc	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116
Michael F. Burgess	officer: Head of Research & Development	C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMRIDGE MA 02142
Stephen P Squinto	director, 10 percent owner	C/O ALEXION PHARMACEUTICALS INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Bhavesh Ashar	officer: Chief Commercial Officer	C/O SPRINGWORKS THERAPEUTICS, 100 WASHINGTON BLVD, STAMFORD CT 05902
Orbimed Capital Gp Vi Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Badreddin Edris	officer: Chief Business Officer	C/O SPRINGWORKS THERAPEUTICS, INC., 100 WASHINGTON BLVD., STAMFORD CT 06902